ABL Bio Inc. (298380.KQ)

KRW 67200.0

(3.07%)

Net Debt Summary of ABL Bio Inc.

ABL Bio Inc.'s latest annual net debt in 2023 was 15.87 Billion KRW , down -4.95% from previous year.
ABL Bio Inc.'s latest quarterly net debt in 2024 Q2 was 42.47 Billion KRW , up 42.78% from previous quarter.
ABL Bio Inc. reported annual net debt of 16.7 Billion KRW in 2022, up 179.47% from previous year.
ABL Bio Inc. reported annual net debt of -21.01 Billion KRW in 2021, up 46.34% from previous year.
ABL Bio Inc. reported quarterly net debt of 42.47 Billion KRW for 2024 Q2, up 42.78% from previous quarter.
ABL Bio Inc. reported quarterly net debt of 10.28 Billion KRW for 2023 Q1, down -38.39% from previous quarter.

Annual Net Debt Chart of ABL Bio Inc. (2023 - 2016)

Historical Annual Net Debt of ABL Bio Inc. (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	15.87 Billion KRW	-4.95%
2022	16.7 Billion KRW	179.47%
2021	-21.01 Billion KRW	46.34%
2020	-39.16 Billion KRW	56.13%
2019	-89.26 Billion KRW	26.85%
2018	-122.03 Billion KRW	-2266.91%
2017	5.63 Billion KRW	286.95%
2016	-3.01 Billion KRW	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	29.74 Billion KRW	87.4%
2024 Q2	42.47 Billion KRW	42.78%
2023 Q1	10.28 Billion KRW	-38.39%
2023 Q4	15.87 Billion KRW	15.22%
2023 Q3	13.77 Billion KRW	-45.56%
2023 Q2	25.3 Billion KRW	145.97%
2023 FY	15.87 Billion KRW	-4.95%
2022 Q1	-82.4 Billion KRW	-292.15%
2022 Q4	16.7 Billion KRW	184.18%
2022 Q3	-19.83 Billion KRW	57.35%
2022 Q2	-46.51 Billion KRW	43.55%
2022 FY	16.7 Billion KRW	179.47%
2021 FY	-21.01 Billion KRW	46.34%
2021 Q2	-22.96 Billion KRW	34.19%
2021 Q4	-21.01 Billion KRW	35.09%
2021 Q3	-32.37 Billion KRW	-41.0%
2021 Q1	-34.89 Billion KRW	0.0%
2020 FY	-39.16 Billion KRW	56.13%
2019 FY	-89.26 Billion KRW	26.85%
2018 FY	-122.03 Billion KRW	-2266.91%
2017 FY	5.63 Billion KRW	286.95%
2016 FY	-3.01 Billion KRW	0.0%

Peer Net Debt Comparison of ABL Bio Inc.

Name	Net Debt	Net Debt Difference
Sam Chun Dang Pharm. Co., Ltd	13.19 Billion KRW	-20.277%
Hyundai Bioscience Co., Ltd.	3.73 Billion KRW	-325.04%
ST Pharm Co.,Ltd.	141.98 Billion KRW	88.82%
Cellid, Co., Ltd.	-1.38 Billion KRW	1245.338%